PEB-Pacific Edge

[LoungeLizard]

Indeed.

Lorraina/Percy's comments just show different strokes for different folks.

Lorraina/Percy more aligned to dividend and retail stocks I suspect.

Other investors are aligned more to little Kiwi companies that can take on the world outside NZ....some also welcome the prospects of significant tax free capital gains.... some examples.

XRO was deemed a risky stock for a many years and the SP has shown some huge historical fluctuations on the path to success. When I first purchased XRO it was a $40 share, then the SP fell as low as $15. I did my research and backed XRO buying more at lower SPs until my av holding SP was in the low $20s...... fast forward to XRO today....... you get the idea.

I've now followed pretty much the same route with; ATM, GTK, IFT, TWR, FPH, IKE etc....(some still in my portfolio and some now gone.)

The trick is to do your research, buy your shares in small increments and continually work at improving your average holding SP by buying more in the 'lows' (but only if you are confident in the products and management's skills.)

Before Novitas my PEB av holding SP cost was $0.40..... this was fine when PEB climbed to around $1.40 and all was rosey...however when Novitas decision crashed the SP, it was a case of not panicking, waiting to see how management handled the issue, then acting... In time I increased my PEB holding by 500% around the 10c mark and am now reaping the rewards.

I think the current iteration of PEB is the best it has ever been and the prospects ahead are exciting.

Holders are now well positioned IMO...... however there will always be other investors who differ.

Followed the same path, LF - bought early on, kept buying through the crash and capital raises,  got my average price down to 16c and now "well-positioned" should coverage be re-instated. I'm holding just shy of 700k shares - more than sensible - but sometimes you have to back your instincts. I did that with ATM not long after they joined NZX and that was a life-changing investment decision. 

[lorraina]

In the 1990s I bought into some small cap Aussie biotech stocks.
All were expecting FDA approval was just around the corner.
Wrong.All failed and went broke.
Having a poor memory 25 years later I thought I had found a winner and posted this on the other channel.
UCM Uscom Ltd
USCOM Limited is engaged in the development, design, manufacture and marketing of premium non-invasive cardiovascular and pulmonary medical devices. The Company manages a network of distribution partners across the world for the sale of its equipment to hospitals and other medical care locations. Its geographic segments include Australia, Asia, the Americas, Europe and Mid East and Africa, and Other Regions.
150,513,275 shares on issue at 17 cents gives a market cap of $28,112,557.
Strong balance sheet,good cash flow,profitable and holding a good amount of cash.Growth for the coming year looks as though it will be out standing,being driven by momentum and new products.
Interesting seeing today UCM's market cap is just $2.8 mil.Managed to get out with my capital intact.
On ASX watch list I have 4DX and ARX,but do not have shares in either.
I have stayed away from TRU TruScreen.
Not a sector I will invest in,however medical supply companies such as EBO,and PGC  interest me.

[winner (n)]

Lorriana ....did you ever have Ventracor early this century. They did artificial hearts.

Ramped like a buggery on forums and share price ups and downs were exciting.

[lorraina]

No .Missed that one.
I did hold Skyepharma in UK.
Can not remember what happened to them.
 

[Left Field]

From a TA perspective a new 'base' is forming around the 20c level now that the 15 Sept breakaway gap between .16 -.17c has been filled.

Encouraging support bodes well for further upside.

[Greekwatchdog]

From a TA perspective a new 'base' is forming around the 20c level now that the 15 Sept breakaway gap between .16 -.17c has been filled.

Encouraging support bodes well for further upside.

Due for 2nd quarter update within the next week, be interesting if they have increased test numbers out of US since intro into guidelines.

Ultimately we will move on + annoucements.

[SuperMario]

Due for 2nd quarter update within the next week, be interesting if they have increased test numbers out of US since intro into guidelines.

Ultimately we will move on + annoucements.

I guess the question is whether test volumes continue to dip because of novitas coverage ending in April, if they increase because AUA guideline awareness increases, or these two factors balance each other out?

[Greekwatchdog]

I guess the question is whether test volumes continue to dip because of novitas coverage ending in April, if they increase because AUA guideline awareness increases, or these two factors balance each other out?

I am looking at the US numbers past Novitas (No point in worrying about them until it gets sorted). 

New clients/contracts etc. Also how things are working out in other markets off low bases.

Lower USD will also have been helpful during 2nd quarter. Any more clinicial evidence being provided.

All about joining the dots

[LoungeLizard]

From a TA perspective a new 'base' is forming around the 20c level now that the 15 Sept breakaway gap between .16 -.17c has been filled.

Encouraging support bodes well for further upside.

Dead right, LF - pushing through to 21c today with good buyer support to go further in the days ahead.

[SuperMario]

I am looking at the US numbers past Novitas (No point in worrying about them until it gets sorted). 

New clients/contracts etc. Also how things are working out in other markets off low bases.

Lower USD will also have been helpful during 2nd quarter. Any more clinicial evidence being provided.

All about joining the dots

Good point!

[Greekwatchdog]

Update attached.
https://www.nzx.com/announcements/460568

2 points of interest

Novitas, our Medicare AdministrativeContractor has announced its intention toconvene a panel of experts called aContractor Advisory Committee(CAC) to "to discuss evidence forthe use of urine-based biomarkersin patients with microhematuria."The CAC is tentatively scheduledfor February 19, 2026 at 6pm ETand demonstrates that Novitasrecognizes the importance ofthe AUA's update to the 2025Microhematuria Guideline andunderstands the strength of theevidence supporting our tests (seepage 5)

Since the non-coverage determination took effectin April, we have continued to seek reimbursementfor Cxbladder Triage on the grounds that Guidelinerecommended tests are medically reasonable andnecessary and therefore eligible for reimbursementunder the US Social Security Act.While initial claims for Triage tests have beendenied as expected, we have filed appeals for asubstantial portion of these claims and expect tohave them heard by an Administrative Law Judge(ALJ). Given the strength of the new evidence from2024 (STRATA) and 2025 (AUA MicrohematuriaGuideline) that was not considered during theestablishment of the LCD, Pacific Edge sees a highprobability of success on appeal.
However, statutory timeframes of the appealsprocess are protracted, and we do not expect theseefforts to begin contributing to revenue until thesecond half of this financial year

[LoungeLizard]

The quarterly numbers aren't great but largely expected.
 Useful information surrounding the CAC meeting and on-going legal appeals. I certainly get the sense of frustration from the CEO, but still a case of being patient. PEB explicitly state that it is a question of when rather than if inclusion is reinstated. Might top up further if there's a dip in the SP. 

[Pierre]

The quarterly numbers aren't great but largely expected.
 Useful information surrounding the CAC meeting and on-going legal appeals. I certainly get the sense of frustration from the CEO, but still a case of being patient. PEB explicitly state that it is a question of when rather than if inclusion is reinstated. Might top up further if there's a dip in the SP. 

A few nervous Nellie's bailing, or profit-taking on this morning's not unexpected news. This presents a good buying opportunity for anyone wanting to top up their holding in anticipation of a positive outcome from Novitas in 2026.
We will likely see a bit of a bounce-back in the SP this afternoon.
I increased my share total by 25% in the recent CR so I'm holding steady right now.

[LoungeLizard]

A few nervous Nellie's bailing, or profit-taking on this morning's not unexpected news. This presents a good buying opportunity for anyone wanting to top up their holding in anticipation of a positive outcome from Novitas in 2026.
We will likely see a bit of a bounce-back in the SP this afternoon.
I increased my share total by 25% in the recent CR so I'm holding steady right now.

Dead right there, Pierre. A few bailing this morning but SP is now up for the day.

I actually thought that the SP would get a lift on some of the encouraging detail in the quarterly report especially the part that said PEB "sees a high probability of success" in their appeal case for "a substantial portion" of retrospective claims to be re-imbursed on the grounds that that they were erroneously denied.
Good strategy to keep lodging claims I thought.

[Pierre]

Dead right there, Pierre. A few bailing this morning but SP is now up for the day.

I actually thought that the SP would get a lift on some of the encouraging detail in the quarterly report especially the part that said PEB "sees a high probability of success" in their appeal case for "a substantial portion" of retrospective claims to be re-imbursed on the grounds that that they were erroneously denied.
Good strategy to keep lodging claims I thought.

Yes, the report was positive, but still speculative, so I guess we cant blame investors for remaining cautious until the probability turns into reality. Once that happens though, it's game on and there will be many regretting their caution at this time.